DTP3: A phase 1/2 trial of DTP3 in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL)

This trial is testing a new medication, DTP3, in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL)

You can share the following ISRCTN.com Identifier with your medical team so they can find out more about the trial: ISRCTN13777452 

Trial aim and background

The aim of this trial is to investigate a new drug called DTP3 in people with DLBCL. It aims to see how effective it is in the treatment of these people, as well as determining a suitable dose which is safe as well as effective.

DTP3 can cause the death of lymphoma cells but not healthy cells in laboratory and early human studies. During a recent first in-human-trial in a small number of patients with myeloma (bone marrow cancer), there were encouraging signs of clinical benefit with few side-effects. This study aims to further investigate this.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.

Who can enter

Anyone over 16 with relapsed or refractory DLBCL may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • Hammersmith Hospital, London
  • Southampton General Hospital, Southampton
  • St James University Hospital, Leeds
  • University College London Hospital, London
  • The Christie, Manchester
  • Cardiff & Vale University Lhb, Cardiff
  • Nottingham University Hospital, Nottingham

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://www.isrctn.com/ISRCTN13777452

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.